XML 16 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenues:    
Total revenue $ 393,572 $ 334,617
Costs and expenses:    
Research and development 494,979 522,723
General and administrative 1,596,338 1,788,594
Foreign currency exchange loss 7,072 4,903
Total costs and expenses 2,396,047 2,460,175
Loss from operations (2,002,475) (2,125,558)
Other income (expense):    
Interest income 88,458 87,443
Gain on sale of Alphazyme 0 60,977
Total other income (expense), net (25,104) 115,962
Net loss $ (2,027,579) $ (2,009,596)
Basic and diluted net loss per common share (in dollars per share) $ (0.07) $ (0.07)
Basic and diluted weighted-average common shares outstanding (in shares) 29,886,665 28,828,282
Related Party [Member]    
Other income (expense):    
Interest expense $ (89,243) $ (21,639)
Nonrelated Party [Member]    
Other income (expense):    
Interest expense (24,319) (10,819)
Research and Development [Member]    
Revenues:    
Total revenue 183,100 334,617
Costs and expenses:    
Cost of revenue 126,480 143,955
Grant [Member]    
Revenues:    
Total revenue 210,472 0
Costs and expenses:    
Cost of revenue $ 171,178 $ 0